READING, Pa., Feb. 13, 2018 /PRNewswire/ -- Research published
by PharmaForce International (PFI) shows 31% of pharmaceutical and
biotech companies are deploying multiple oncology sales force
sleeves that support an individual product. This strategic approach
is employed in an effort to capitalize on opportunities to increase
sales across indications for the same medication.
These findings, along with more granular data are contained in
PFI's Oncology benchmarking study. This well-respected and widely
referenced report is in its 17th annual edition and
examines a cross-section of over 35 companies in the oncology
therapeutic area.
Joyce Wedemeyer, Director of
Marketing and Sales at PharmaForce International, notes that many
recently approved oncology medications have been granted multiple
indications by the FDA.
"A wave of immuno-oncology drugs
have been approved by the FDA in the past few years. At the same
time, opportunities to improve patient outcomes are presenting
themselves by pairing these new medications with others already
available to the oncologist."
"In many instances, companies
market these new indications as being patient-specific, and a
specialized sales approach is necessary to drive product uptake
across tumor types," Wedemeyer said.
"Combination and targeted
therapies are accelerating trends in the oncology space," she
continued. "We envision a day in the not-too-distant future where
many types of cancers may be managed over time as chronic
diseases."
Additional industry trends captured in the report include
insights specific to:
- Specialized HEOR approaches
- Expanded roles for Key Account Managers
- Recently deployed field-based Marketing Managers
- Adoption of diagnostic genetic testing personnel
- Emerging biosimilar competitors
- Newly deployed Thought Leader Teams to engage Key Opinion
Leaders
For more information on the report mentioned above, please
contact Joyce
Wedemeyer at Joyce.Wedemeyer@strategicreports.com or
by phone at 610-370-2906.
PharmaForce International (PFI) is a competitive
intelligence firm with over two decades of experience in the
pharmaceutical and biotech industries. PFI has become the market
leader in commercial operations benchmarking and competitive
intelligence. The globally focused company employs marketplace
experts uniquely qualified to perform research required by clients
in most major pharmaceutical markets around the world,
including Europe, India, Japan, Latin America,
and the United
States.
View original content with
multimedia:http://www.prnewswire.com/news-releases/pharmaforce-international-research-indicates-continued-migration-toward-specialty-oncology-sales-forces-and-novel-breakthrough-medical-therapy-options-for-cancer-patients-300596073.html
SOURCE PharmaForce International